Physician profile
David L Tyson
NPI 1497702708
$4,683.62
in general payments reported to CMS, 2019-2025
42 companies · $654 in 2025
The $654 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,293 · 2020: $573 · 2021: $436 · 2022: $534 · 2023: $659 · 2024: $534 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $683.40 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $459.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $375.84 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.15 | 2019-2024 | Jardiance |
| Pfizer INC. | $245.98 | 2019-2023 | |
| Abbvie INC. | $230.75 | 2019-2024 | Vraylar, Ubrelvy, Synthroid |
| Astellas Pharma US INC | $216.95 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $152.66 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Amgen INC. | $145.75 | 2019-2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $143.37 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.48 | 2020-2024 | Xifaxan, Trulance |
| Eisai INC. | $122.88 | 2019-2025 | |
| Inspire Medical Systems, INC. | $119.95 | 2023-2025 | Inspire |
| Lilly USA, LLC | $109.85 | 2022-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $100.52 | 2019-2025 | Eliquis |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.